+396.0%
NVDA vs GSK
+48.7%
+347.3%
-36.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.9% | +0.2% | -1.1% | -0.9% |
| 7D | -0.3% | -3.6% | +3.3% | -0.7% |
| 30D | +2.8% | -5.9% | +8.7% | +2.3% |
| 3M | +7.4% | -4.3% | +11.7% | +7.1% |
| 6M | +22.6% | -10.8% | +33.4% | +21.8% |
| YTD | +20.1% | +1.8% | +18.3% | +20.8% |
| 1Y | +31.2% | +23.5% | +7.7% | +33.8% |
| All | +396.0% | +48.7% | +347.3% | +412.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling